WAVEMAN · COMPANY

RLMD · Relmada Therapeutics, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

RLMD

Name: RELMADA THERAPEUTICS, INC. (RLMD) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

RELMADA THERAPEUTICS, INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001553643

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

83 funds added or opened last quarter

more than 58% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

$9.8M repurchased, FY to 2026-06-30

below 71% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

83 funds added or opened positions in the latest 13F quarter, of 127 holders.

2 trial completion dates slipped in the last 90 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +212.0%

+212.0%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 83 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for RELMADA THERAPEUTICS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

TRAVERSA SERGIO

Chief Executive Officer

BUY

2025-12-15

27,500.0

$113.3K

Shenouda Maged

Chief Financial Officer

BUY

2025-12-15

11,665.0

$48.1K

Ence Chuck

CAO and COO

BUY

2025-11-05

136,000.0

$299.2K

TRAVERSA SERGIO

Chief Executive Officer

BUY

2025-11-05

272,500.0

$599.5K

Shenouda Maged

Chief Financial Officer

BUY

2025-11-05

500,000.0

$1.1M

48 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 43 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Jupiter Topco LLC

11,164,803.0 sh

$77.3M

BlackRock, Inc.

7,426,780.0 sh

$51.4M

Squadron Capital Management LLC

7,350,000.0 sh

$50.9M

Venrock Adviser, LLC

6,844,305.0 sh

$47.4M

Spruce Street Capital LP

6,391,328.0 sh

$44.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

AdvisorShares Psychedelics ETF

$2.1M POSITION · AS OF 2026-03-31

10.2%

SIMT Tax-Managed Small/Mid Cap Fund

$633.9K POSITION · AS OF 2026-03-31

0.1%

VANGUARD EXTENDED MARKET INDEX FUND

$5.7M POSITION · AS OF 2026-03-31

0.0%

Victory Extended Market Index Fund

$52.1K POSITION · AS OF 2026-04-30

0.0%

Invesco RAFI US 1500 Small-Mid ETF

$168.7K POSITION · AS OF 2026-04-30

0.0%

Fidelity Extended Market Index Fund

$1.5M POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 9 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

1 ACTIVE

Phase 3

1 ACTIVE

Not applicable

0 ACTIVE

What changed recently

A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-mus

2026-09-03 · Completion moved 2029-09 → 2029-12

Phase 3

A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC

2026-09-03 · Completion moved 2025-08 → 2027-11

Phase 2

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
OPERATING INCOME	$-59.1M	$-83.9M	$-103.7M	$-161.2M
NET INCOME	$0	$0	$0	$-157.0M
EPS (DILUTED)	-1.45	-2.65	-3.28	-5.30
OPERATING CASH FLOW	$-45.8M	$-51.8M	$-51.7M	$-103.8M
CASH	$3.5M	$3.9M	$4.1M	$5.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE